查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951921

寡核苷酸合成市场分析及预测（至2035年）：类型、产品类型、服务、技术、应用、形式、最终用户、製程、功能、阶段

Oligonucleotide Synthesis Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Form, End User, Process, Functionality, Stage
出版日期: | 出版商: Global Insight Services | 英文 302 Pages | 商品交期: 3-5个工作天内

价格
简介目录

寡核苷酸合成市场预计将从2024年的62亿美元成长到2034年的154亿美元，复合年增长率约为10.2%。寡核苷酸合成市场涵盖短链DNA或RNA分子的生产，这些分子在基因研究、诊断和治疗中发挥关键作用。该市场的成长动力主要来自合成生物学、个人化医疗的进步以及对核酸治疗方法日益增长的需求。为了满足研究和临床应用中对高品质寡核苷酸日益增长的需求，合成技术的创新性、可扩展性和成本效益是关键所在。

寡核苷酸合成市场正经历强劲成长，这主要得益于寡核苷酸在研究和治疗领域应用的不断拓展。以细分市场来看，合成寡核苷酸细分市场由于其在诊断和治疗应用中的重要作用，呈现最高的成长率。针对特定研究需求量身订做的寡核苷酸需求显着成长，反映出其在个人化医疗中的重要性。耗材细分市场（包括试剂和酶，它们是高效合成过程的必需品）的成长率排名第二。服务细分市场（包括契约製造和定序服务）也因生技公司外包趋势而备受关注。自动化合成仪因其精准性和扩充性而变得不可或缺，进一步增强了市场动态。此外，对基于RNA的疗法的日益关注以及新型合成技术的开发是关键驱动因素，为市场参与企业创造了盈利的机会。预计研发投入和策略联盟将进一步推动市场扩张和创新。

市场区隔
类型 定制和预製寡核苷酸
产品 合成寡核苷酸、试剂和设备
服务 客製合成、寡核苷酸纯化和寡核苷酸修饰
科技 固相合成、液相合成、酵素合成
目的 研究、治疗、诊断、基因合成
形式 液态冻干产品
最终用户 学术研究机构、製药公司、生技公司、诊断实验室
过程 DNA合成，RNA合成
功能 反义寡核苷酸、siRNA、miRNA
步 临床前、临床、商业化

寡核苷酸合成市场正经历市场份额的动态变化，这主要受竞争性定价策略和创新产品推出的推动。各公司正利用最尖端科技来丰富产品线，并吸引来自不同产业的多元化客户群。对客製化寡核苷酸的需求正在迅速增长，进一步加剧了主要企业之间的竞争。这种竞争环境促进了策略联盟和合作，使公司能够扩展产品系列併巩固市场地位。从竞争标竿分析的角度来看，主要参与者不断评估其市场地位，以优化其策略倡议。监管影响至关重要，严格的指导方针影响产品开发和市场准入。严格的合规标准正在重塑市场格局，尤其是在北美和欧洲等法规结构更严格的地区。各公司正在加大研发投入，以应对这些监管挑战，并确保产品的有效性和安全性。这种策略重点对于在竞争激烈的环境中实现持续成长至关重要。

主要趋势和驱动因素：

受个人化医疗和生物技术进步的推动，寡核苷酸合成市场正经历强劲成长。关键趋势包括对客製化寡核苷酸的需求不断增长，这些寡核苷酸对于诊断、治疗和研究等应用至关重要。基因编辑技术（尤其是CRISPR）的兴起显着促进了市场发展，因为研究人员和企业都在寻求精准高效的合成技术。此外，合成生物学的扩展也推动了对高品质寡核苷酸的需求。基因体学和蛋白质体学研究投入的增加也支撑了这个趋势。医疗产业转型为精准医疗也是一个关键的驱动因素，而精准医疗高度依赖寡核苷酸为基础的治疗方法。此外，遗传性感染疾病的日益普及也推动了对创新寡核苷酸解决方案的需求。新兴市场医疗基础设施的不断改进正在加速推进先进生物技术的应用，这带来了许多机会。能够提供经济高效且扩充性的合成解决方案的公司将获得竞争优势。此外，将自动化和人工智慧融入合成过程，提高了效率并节省了成本，有可能进一步推动这个充满活力的市场的成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 客製化寡核苷酸
    • 预製寡核苷酸
  • 市场规模及预测：依产品划分
    • 合成寡核苷酸
    • 试剂
    • 装置
  • 市场规模及预测：依服务划分
    • 客製合成
    • 寡核苷酸纯化
    • 寡核苷酸修饰
  • 市场规模及预测：依技术划分
    • 固相合成
    • 溶液相合成
    • 酵素合成
  • 市场规模及预测：依应用领域划分
    • 研究
    • 治疗药物
    • 诊断
    • 基因合成
  • 市场规模及预测：依类型
    • 液体
    • 冻干产品
  • 市场规模及预测：依最终用户划分
    • 学术研究机构
    • 製药公司
    • 生技公司
    • 诊断检查室
  • 市场规模及预测：依製程划分
    • DNA合成
    • RNA合成
  • 市场规模及预测：依功能划分
    • 反义寡核苷酸
    • siRNA
    • 微型RNA
  • 市场规模及预测：依阶段划分
    • 临床前阶段
    • 临床
    • 商业的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Integrated DNA Technologies
  • Eurofins Genomics
  • LGC Biosearch Technologies
  • Gen Script Biotech
  • Twist Bioscience
  • Bio-Synthesis
  • Sigma-Aldrich
  • Biomers
  • ATDBio
  • Tri Link Bio Technologies
  • Gene Link
  • Bioneer
  • LGC Axolabs
  • Alnylam Pharmaceuticals
  • Chem Genes
  • Glen Research
  • Kaneka Eurogentec
  • Nitto Denko Avecia
  • Synbio Technologies
  • Base Pair Biotechnologies

第九章：关于我们

简介目录
Product Code: GIS20211

Oligonucleotide Synthesis Market is anticipated to expand from $6.2 billion in 2024 to $15.4 billion by 2034, growing at a CAGR of approximately 10.2%. The Oligonucleotide Synthesis Market encompasses the production of short DNA or RNA molecules, pivotal in genetic research, diagnostics, and therapeutics. This market is driven by advancements in synthetic biology, personalized medicine, and increased demand for nucleic acid-based therapies. Key focuses include innovation in synthesis techniques, scalability, and cost-effectiveness to meet the rising need for high-quality oligonucleotides in research and clinical applications.

The Oligonucleotide Synthesis Market is experiencing robust growth, propelled by the increasing application of oligonucleotides in research and therapeutics. Among the segments, the synthesized oligonucleotides segment is the top performer, driven by its critical role in diagnostics and therapeutic applications. Custom oligonucleotides, tailored for specific research needs, are witnessing substantial demand, reflecting their significance in personalized medicine. The consumables sub-segment, encompassing reagents and enzymes, is the second-highest performer, essential for efficient synthesis processes. The services segment, including contract manufacturing and sequencing services, is also gaining traction due to the outsourcing trend among biotech firms. Automated synthesizers are becoming indispensable, offering precision and scalability, thus enhancing market dynamics. Furthermore, the growing focus on RNA-based therapeutics and the development of novel synthesis technologies are key drivers, presenting lucrative opportunities for market participants. Investments in R&D and strategic collaborations are expected to further propel market expansion and innovation.

Market Segmentation
TypeCustom Oligonucleotides, Pre-designed Oligonucleotides
ProductSynthesized Oligonucleotides, Reagents, Equipment
ServicesCustom Synthesis, Oligo Purification, Oligo Modification
TechnologySolid-phase Synthesis, Solution-phase Synthesis, Enzymatic Synthesis
ApplicationResearch, Therapeutics, Diagnostics, Gene Synthesis
FormLiquid, Lyophilized
End UserAcademic Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Diagnostic Laboratories
ProcessDNA Synthesis, RNA Synthesis
FunctionalityAntisense Oligonucleotides, siRNA, miRNA
StagePreclinical, Clinical, Commercial

The Oligonucleotide Synthesis Market is experiencing dynamic shifts in market share, driven by competitive pricing strategies and the introduction of innovative products. Companies are leveraging cutting-edge technologies to enhance product offerings, thereby attracting a diverse clientele across various sectors. The market is witnessing a surge in demand for custom oligonucleotides, which is further fueling competition among key players. This competitive environment is fostering strategic alliances and collaborations, enabling firms to expand their product portfolios and enhance their market presence. In terms of competition benchmarking, major players are continually assessing their market positions to optimize their strategic initiatives. Regulatory influences play a pivotal role, with stringent guidelines impacting product development and market entry. The market landscape is shaped by rigorous compliance standards, particularly in regions like North America and Europe, where regulatory frameworks are more stringent. Companies are investing in research and development to navigate these regulatory challenges, ensuring product efficacy and safety. This strategic focus is essential for sustaining growth in a highly competitive environment.

Geographical Overview:

The Oligonucleotide Synthesis Market is witnessing remarkable growth across various regions, each characterized by unique dynamics. North America leads, driven by substantial investments in biotechnology and pharmaceutical research. The presence of major biotech firms and research institutions further accelerates market expansion. Europe follows closely, with a strong emphasis on innovative healthcare solutions and government support for biotechnology. The region's robust regulatory framework enhances market stability and growth prospects. In Asia Pacific, rapid advancements in genomics and personalized medicine are propelling market growth. Countries like China and India are emerging as key players, fueled by increasing investments in research and development. Latin America and the Middle East & Africa present burgeoning opportunities. Latin America is experiencing a surge in biotech startups and collaborations, while the Middle East & Africa are investing in healthcare infrastructure to support oligonucleotide synthesis. These regions are recognizing the potential of oligonucleotide technologies in advancing medical research and therapeutic applications.

The global oligonucleotide synthesis market is navigating complex challenges shaped by tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, key players in biotechnology, are adapting to trade tensions by enhancing domestic capabilities and forging strategic alliances. China is intensifying its focus on self-reliance in oligonucleotide production, driven by export limitations and geopolitical pressures. Taiwan continues to be a pivotal supplier, yet remains vulnerable to regional conflicts. The parent market is experiencing robust growth, propelled by advancements in personalized medicine and genetic research. By 2035, the market is anticipated to evolve through strategic diversification and technological innovation. Middle East conflicts contribute to supply chain disruptions and volatile energy prices, indirectly influencing production costs and market stability.

Key Trends and Drivers:

The oligonucleotide synthesis market is experiencing robust growth, driven by advancements in personalized medicine and biotechnology. Key trends include the increasing demand for custom oligonucleotides, which are essential in applications such as diagnostics, therapeutics, and research. The rise of gene editing technologies, particularly CRISPR, is significantly boosting the market as researchers and companies seek precise and efficient synthesis techniques. Moreover, the expansion of synthetic biology is fueling the need for high-quality oligonucleotides. This trend is supported by the growing investments in genomics and proteomics research. The healthcare industry's shift towards precision medicine is another crucial driver, as it relies heavily on oligonucleotide-based therapies. Additionally, the increasing prevalence of genetic disorders and infectious diseases is propelling the demand for innovative oligonucleotide solutions. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and the adoption of advanced biotechnologies is accelerating. Companies that provide cost-effective and scalable synthesis solutions stand to gain a competitive edge. Furthermore, the integration of automation and artificial intelligence in synthesis processes is poised to enhance efficiency and reduce costs, offering further growth potential in this dynamic market.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Custom Oligonucleotides
    • 4.1.2 Pre-designed Oligonucleotides
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Synthesized Oligonucleotides
    • 4.2.2 Reagents
    • 4.2.3 Equipment
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Custom Synthesis
    • 4.3.2 Oligo Purification
    • 4.3.3 Oligo Modification
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Solid-phase Synthesis
    • 4.4.2 Solution-phase Synthesis
    • 4.4.3 Enzymatic Synthesis
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Research
    • 4.5.2 Therapeutics
    • 4.5.3 Diagnostics
    • 4.5.4 Gene Synthesis
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Liquid
    • 4.6.2 Lyophilized
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Academic Research Institutes
    • 4.7.2 Pharmaceutical Companies
    • 4.7.3 Biotechnology Companies
    • 4.7.4 Diagnostic Laboratories
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 DNA Synthesis
    • 4.8.2 RNA Synthesis
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Antisense Oligonucleotides
    • 4.9.2 siRNA
    • 4.9.3 miRNA
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Preclinical
    • 4.10.2 Clinical
    • 4.10.3 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Form
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Functionality
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Form
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Functionality
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Form
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Functionality
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Form
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Functionality
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Form
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Functionality
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Form
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Functionality
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Form
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Functionality
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Form
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Functionality
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Form
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Functionality
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Form
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Functionality
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Form
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Functionality
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Form
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Functionality
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Form
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Functionality
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Form
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Functionality
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Form
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Functionality
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Form
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Functionality
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Form
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Functionality
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Form
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Functionality
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Form
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Functionality
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Form
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Functionality
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Form
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Functionality
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Form
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Functionality
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Form
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Functionality
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Form
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Functionality
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Integrated DNA Technologies
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Eurofins Genomics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 LGC Biosearch Technologies
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Gen Script Biotech
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Twist Bioscience
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Bio- Synthesis
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Sigma- Aldrich
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Biomers
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 ATDBio
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Tri Link Bio Technologies
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Gene Link
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bioneer
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 LGC Axolabs
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Alnylam Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Chem Genes
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Glen Research
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Kaneka Eurogentec
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Nitto Denko Avecia
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Synbio Technologies
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Base Pair Biotechnologies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us